Guide · Updated 2026-06-28
Formulary Management for Bioengineered Tissues
Bioengineered tissue formularies sprawl quickly because each clinical service line champions its preferred product. The procurement-driven approach: tier by indication, require second-source within each tier, and enforce a quarterly SKU review.
Tier by indication, not by product
Most overspend traces to redundant SKUs covering the same clinical use case. Build the formulary around indications (chronic DFU, VLU, surgical reconstruction, burn) and assign one primary and one alternate product per indication. Anything beyond two SKUs in the same tier must be justified annually.
Second-source every tier
Single-source contracts expose the formulary to manufacturer shortages and price escalation. Negotiate dual-source for every primary indication; commit volume but reserve a documented alternate source the system can route to within 48 hours.
Quarterly review cadence
Bind formulary review to the CMS ASP file release cadence (quarterly). The review compares ASP changes, contract pricing, waste rate by site, and any new LCD updates. Products that drift on price, evidence, or LCD coverage are flagged for swap.
Kill the long tail
Quarterly, identify any SKU with <5% of category volume. Default action: remove from formulary unless a documented clinical exception exists. Long-tail SKUs are the primary driver of waste and contract leakage.
Key takeaways
- Tier by indication, primary + alternate per tier.
- Second-source every tier — no single-source contracts.
- Review quarterly on the CMS ASP cycle.
- Cut SKUs below 5% category volume.
More from the playbook
- Negotiating Wound Care Vendor Rebates
- Reducing Biological Wound Graft Waste in the OR and Wound Center
- Inpatient to Outpatient Wound Graft Billing Transition
- Cold Chain Logistics for Cryopreserved Wound Grafts
- 340B Drug Pricing and Wound Skin Substitutes
- MAC Jurisdiction Coverage Variance for Skin Substitutes
Part of the 2026 Advanced Wound Graft Procurement Playbook.